Bispecific antibodies for cancer therapy: the light at the end of the tunnel? - Test2 - elhamkhani - TriplyDB

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

http://www.wikidata.org/entity/Q24644083

about

Lost in Translation (LiT): IUPHAR Review 6 Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag T cell receptor mimic antibodies for cancer therapy Bispecific antibodies and their applications Challenges in Antibody Development against Tn and Sialyl-Tn Antigens Site-specific functionalization of proteins and their applications to therapeutic antibodies Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer Immunotherapeutic organoids: a new approach to cancer treatment Novel immunotherapies for hematologic malignancies Monoclonal antibodies for the treatment of cancer Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface Bispecific T-cell engagers for cancer immunotherapy.Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.The development of bispecific antibodies and their applications in tumor immune escape.Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.Prodrug applications for targeted cancer therapy.A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.O-glycosylation of glycine-serine linkers in recombinant Fc-fusion proteins: attachment of glycosaminoglycans and other intermediates with phosphorylation at the xylose sugar subunit.Highly efficient, in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-FasL.Structural and functional characterization of the trifunctional antibody catumaxomab Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Protein conjugation with genetically encoded unnatural amino acids.Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity Homogeneous bispecifics by disulfide bridging.Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis.Combinatorial antibody libraries: new advances, new immunological insights.In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy Nanocell targeting using engineered bispecific antibodies.Fab-based bispecific antibody formats with robust biophysical properties and biological activity Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation Chemically programmed bispecific antibodies that recruit and activate T cells Rational design of antirheumatic prodrugs specific for sites of inflammation.Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.

P2860

Q24289150-BDE48FC2-EAC6-4A57-8494-25F332C83ADB Q24601129-4EBDA201-2505-4E55-B129-D22593878306 Q26768271-DDD33CEE-981F-4190-969C-C9DBBC00E711 Q26774024-59BD3FF4-B09D-4E91-B44A-D91DB5A9C3B1 Q26798183-AAF38971-81FB-4023-9899-1FF6E37F6B7A Q26830699-03F64668-F00C-454C-9D1C-5EA6A2170ACC Q26852215-62DC1B2A-754A-4B57-A41C-5E626B244C1F Q26853431-2191C40D-655A-4A7F-865A-8305CB36F711 Q27004436-50A61D06-D543-4832-9DCC-2CCB8FE61875 Q27025966-B7B10543-4CD1-45A6-AF48-22490DAE5495 Q27688974-C7901591-0E3B-48DA-8C89-A3D361B550C3 Q27693313-728040E2-4A6A-4C6A-9641-8947AA8B0084 Q33576953-187B20CF-97E8-4237-BCAA-5008882F0D83 Q33630292-95DDBCFF-5E74-47B0-A12E-7A7B8CE17F2B Q34074743-A0094D9B-545F-4315-B67A-F276F5906914 Q34099780-437D9E89-D557-4C1E-AE2B-F9635E782D40 Q34221898-275A0F93-DE03-4113-A7B9-13FCA747E406 Q34223974-8AFF8266-E4E7-435B-A5BE-298D54F9796A Q34306584-F20FC115-386E-4CFF-9D77-E8EC341AC052 Q34619043-1EEA4E4F-8B5B-4352-A22D-CCB463640898 Q34817365-D2A64C60-3B03-4228-AAFA-399A9BE801D4 Q34838057-54ABD1E2-CDCB-40D2-9D98-FE12C69295BD Q34986422-E2853CFC-439E-41FF-B6AC-BA46BE450731 Q35090965-6A1C26C9-01AA-4FFA-A7BA-FAD2819582D2 Q35146077-AF09D363-5A0F-4DA4-BA5E-1992DE4A772B Q35199371-FF298430-1ED8-4C7E-BE29-AC1863794EDE Q35613233-FAEF8C9A-7F88-454F-93D9-5E0FCA272C1C Q35692638-9238C166-1149-47F9-9354-4888CD4F4846 Q35808466-BCA8C4A0-955C-48BE-BC44-270A2A96628C Q35822172-742F0998-78DD-4E4D-8505-6CD575D552BF Q35913704-F3E39627-203E-41A8-A395-9B431975B606 Q36067103-C31C7FE1-F9BD-4FA3-A26F-7144BEADB5F6 Q36083324-5CF28845-20DC-4FC3-A548-F9CD79178E5B Q36211456-082FEA8D-5A88-4CA9-BBC9-CD324F3FB002 Q36213193-5825B45D-4DEE-4465-B90C-BFDA5515295D Q36216009-283042A5-A590-45F9-9E8C-AB598F50C2DC Q36216092-4BCC4897-9CCF-44EB-9294-83F59A285D7C Q36217175-0BD56F52-58B0-48D2-BEC6-55460496E3EF Q36799824-AA7AE33E-BCE4-4FE7-ADD3-8DEB927B0127 Q36821533-F31AE036-2DB6-4074-A6BD-ADE236029387

P2860

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

http://www.wikidata.org/entity/Q24644083

description

2009 nî lūn-bûn

@nan

2009 թուականին հրատարակուած գիտական յօդուած

@hyw

2009 թվականին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@ast

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@en

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@nl

type

label

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@ast

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@en

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@nl

prefLabel

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@ast

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@en

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@nl

P1433

Q24644083-B27C787F-B13B-4698-845C-E23B6347A3D9

P1476

Q24644083-59486F5D-C4B7-4009-BA42-D979DDEF32D8

P2093

Q24644083-77B240AC-DE8C-4736-8A6C-56284A6221B5

Q24644083-8CE77913-B163-49EC-AB78-2EC28D72E23A

P2860

Q24644083-0E0FDEFA-E649-4058-8791-809B9CA66611

Q24644083-10EC5DD3-DFA5-4164-A3C2-6150CF7C2D10

Q24644083-170470C1-1D99-4764-8B91-55EDA470E4DE

Q24644083-1F4B0340-86E7-4EA5-9372-84338FF006CD

Q24644083-2166727F-8410-46F2-9E12-138FBA3EB381

Q24644083-261D07DB-F7F5-4832-B3EC-E768349D85EE

Q24644083-27A11DB8-1884-4D33-992C-AD5CB1AC51D2

Q24644083-27CBC0D6-8B74-4767-93B8-963C42245F49

Q24644083-32FF265C-246E-4232-B379-9A708500D1D8

Q24644083-33F3835D-1E15-4ACB-9D47-8E90FEC0C37B

P304

Q24644083-A40287A7-9363-4E99-A02E-1DC6CE5BB5B7

P31

Q24644083-6E9D2BF4-8DA6-4D6E-A373-F748B08B81F0

P3181

Q24644083-53053F5F-4B96-449A-80E6-CB2A8D544FB2

P356

Q24644083-481BF3F6-C461-4565-BBA6-7461D3525DD9

P407

Q24644083-13B4D680-AC12-4EF5-9C43-6BB8374664A6

P433

Q24644083-7EEE07DE-ADF4-4ABE-AFFB-B804EE921DC7

P478

Q24644083-D4CFDE61-239F-4392-A179-1690299A2097

P50

Q24644083-1ADD1146-8850-40E1-94F5-3026EA171214

Q24644083-A9293B76-77AF-470F-B531-6FAA9F8B565F

P577

Q24644083-A1305C26-B6DA-4F17-8E14-68581A52DBEE

P5875

Q24644083-8B44D516-0692-4DD9-BFF9-3933BBE96CE6

P698

Q24644083-8839C9D7-9F69-4444-A212-EF424491D620

P921

Q24644083-8D0E00B9-1D25-4F20-A9B3-89D929856A5F

P932

Q24644083-D74BAE7E-47A9-4095-9BDF-B8E5486B15DC

P3181

P356

P1433

Monoclonal Antibodies

P1476

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

@en

P2093

Daniel Baty

http://www.w3.org/2001/XMLSchema#string

Patrick Chames

http://www.w3.org/2001/XMLSchema#string

P2860

"Diabodies": small bivalent and bispecific antibody fragments

Continuous cultures of fused cells secreting antibody of predefined specificity

Two new trifunctional antibodies for the therapy of human malignant melanoma

Bispecific T-cell engaging antibodies for cancer therapy

The emerging role of EpCAM in cancer and stem cell signaling

Single-domain antibodies as building blocks for novel therapeutics

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

P304

539-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4478355

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/MABS.1.6.10015

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24246141

http://www.w3.org/2001/XMLSchema#string

P698

20073127

http://www.w3.org/2001/XMLSchema#string

P921

P932

2791310

http://www.w3.org/2001/XMLSchema#string